Stock SYNGENE SYNGENE INTERNATIONAL LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

News Syngene International Limited Bombay S.E.

Equities

SYNGENE

INE398R01022

Market Closed - Bombay S.E.
Other stock markets
 11:00:48 30/04/2024 BST 		5-day change 1st Jan Change
689 INR -1.19% Intraday chart for Syngene International Limited -1.75% -1.74%
04-26 Jefferies Downgrades Syngene International to Underperform From Hold, Adjusts Price Target to INR620 From INR690 MT
04-25 Transcript : Syngene International Limited, Q4 2024 Earnings Call, Apr 25, 2024

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Jefferies Downgrades Syngene International to Underperform From Hold, Adjusts Price Target to INR620 From INR690
MT
Transcript : Syngene International Limited, Q4 2024 Earnings Call, Apr 25, 2024
Syngene International Limited Recommends Final Dividend for the Financial Year 2024
CI
Syngene International Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024
CI
Syngene International Limited Reports Earnings Results for the Full Year Ended March 31, 2024
CI
INDIA STOCKS-Financials drag Indian shares, hit by fading US rate cut hopes
RE
Syngene Biologics Manufacturing Facility to Be Operational for U.S. and European Customers from Mid-Year
CI
Bristol Myers CEO says India to have largest R&D presence outside US by 2025
RE
Jefferies Adjusts Syngene International’s Price Target to INR690 From INR770, Keeps at Hold
MT
Syngene International Posts Gains in Fiscal Q3 Consolidated Net Profit
MT
Transcript : Syngene International Limited, Q3 2024 Earnings Call, Jan 25, 2024
Syngene International Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
CI
Syngene International Limited Appoints Mr. Sibaji Biswas as Additional Director Designated as Executive Director, Effective on April 01, 2024
CI
Syngene International Completes Acquisition of Stelis Biopharma's Biologics Plant
MT
Syngene International Limited completed the acquisition of Unit 3 biologics manufacturing facility in Bangalore from Stelis Biopharma Private Limited for INR 6.2 billion.
CI
FOCUS -Indian drug manufacturers benefit from Big Pharma interest beyond China
RE
Syngene International COO Steps Down
MT
Syngene International Limited Announces Resignation of Mahesh Bhalgat as Chief Operating Officer, Effective January 31, 2024
CI
Syngene International Limited Announces Resignation of Carl Decicco as Non-Executive Director
CI
Transcript : Syngene International Limited, Q2 2024 Earnings Call, Oct 18, 2023
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SYNGENE Stock
  4. SYNGENE Stock
  5. News Syngene International Limited